Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for LigaChem Biosciences Inc., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the National Pension Service's acquisition of shares in 'LigaChem Biosciences', crossing the 5% threshold. This falls under the category of Major Shareholding Notification.
2025-07-02 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status by Trust Agreement' (신탁계약등에의한취득상황보고서) filed by LigaChem Biosciences with the Financial Supervisory Service (FSS) of South Korea. It details the company's purchase of its own shares through a trust contract with Mirae Asset Securities. This falls under the category of a company buying back its own shares, which is classified as 'Transaction in Own Shares' (POS).
2025-06-27 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an announcement regarding an upcoming 'Investor Relations' (IR) event titled 'LigaChemBio Global R&D Day 2025'. It provides the date, location, purpose, and details of the presentation. Since it is an announcement of an event and states that the actual presentation materials will be posted on the company website on the day of the event, it falls under the category of a Report Publication Announcement or general regulatory notification regarding an event, which fits the 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) category. Given the specific nature of announcing an IR event, 'RNS' is the most appropriate fallback for this regulatory disclosure.
2025-06-26 Korean
투자판단관련주요경영사항 ('LCB97'관련 마일스톤 기술료 수령)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from LigaChem Biosciences regarding the receipt of a milestone payment for a previously disclosed technology transfer agreement ('LCB97'). It is a specific disclosure of a material business event (major management matter) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A, dividends, or share issues, and is a standard regulatory disclosure of a business event, it is classified as a Regulatory Filing (RNS).
2025-06-11 Korean
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from LigaChem Biosciences regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing the signing of a joint research and antibody technology licensing agreement with NovaRock Biotherapeutics. This type of disclosure, which details a specific business contract or partnership, falls under the category of general regulatory announcements as it does not fit into specific categories like M&A (which usually refers to corporate takeovers) or financial reports. Therefore, it is classified as a Regulatory Filing (RNS).
2025-06-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.